A nurse is caring for a client who is mechanically ventilated and receiving propofol intravenously. Which of the following manifestations should the nurse identify as a complication of administration?

A) Increase in bowel function: Propofol is a sedative-hypnotic agent commonly used for induction and maintenance of anesthesia and sedation for procedures such as colonoscopies. While propofol may affect gastrointestinal motility, it typically leads to a decrease rather than an increase in bowel function. Therefore, an increase in bowel function would not be an expected adverse effect of propofol administration.

B) Increase in heart rate: Propofol generally has a depressant effect on the cardiovascular system, leading to a decrease rather than an increase in heart rate. It causes vasodilation and can result in hypotension and bradycardia, especially during induction of anesthesia. Therefore, an increase in heart rate would not be an expected adverse effect of propofol administration.

C) Decrease in respiratory rate: Respiratory depression is a well-known adverse effect of propofol. It acts as a potent central nervous system depressant, leading to dose-dependent respiratory depression. This effect is more pronounced when propofol is used for deeper levels of sedation or anesthesia. Therefore, monitoring for a decrease in respiratory rate is essential during and after propofol administration to prevent hypoxemia and respiratory compromise.

D) Decrease in body temperature: Propofol infusion syndrome (PRIS) is a rare but potentially fatal complication associated with prolonged high-dose propofol administration. Among its manifestations are metabolic acidosis, rhabdomyolysis, hyperlipidemia, and ultimately, multi-organ failure. However, a decrease in body temperature is not a characteristic feature of PRIS. Instead, hyperthermia or an increase in body temperature may occur as part of the syndrome. Therefore, monitoring for a decrease in body temperature is not a typical adverse effect of propofol administration.

D) Calcium: Calcium supplements can interfere with the absorption of levothyroxine when taken concurrently. Levothyroxine absorption can be significantly reduced if taken with calcium-containing supplements or foods high in calcium. Therefore, clients should wait at least 4 hours after taking levothyroxine before consuming calcium supplements to ensure optimal absorption of the thyroid medication.

A) Zinc: Zinc supplements do not significantly interfere with the absorption of levothyroxine. While zinc can bind to levothyroxine and potentially decrease its absorption, the effect is minimal compared to calcium. However, it is generally recommended to take zinc supplements at least 4 hours apart from levothyroxine to avoid any potential interaction.

B) Vitamin C: Vitamin C supplements do not interfere with the absorption of levothyroxine and can be taken concurrently without significant interactions. There is no need for clients to wait a specific amount of time between taking levothyroxine and vitamin C supplements.

C) Ginkgo biloba: Ginkgo biloba supplements have not been shown to have a significant impact on the absorption of levothyroxine. However, given the variability in individual responses to supplements, it is still prudent to separate the administration of levothyroxine and ginkgo biloba by at least 4 hours to minimize any potential interactions.